| FDA Rejects Proposed Chronic Kidney Disease Indication for Vytorin - Forbes |
|
|
Forbes As a consolation prize, however, the agency approved a new label for Vytorin that will incorporate the results of SHARP (Study of Heart and Renal Protection), which found that Vytorin reduced the incidence of major vascular events in patients with ... New FDA Approved Labeling For VYTORIN® (Ezetimibe/Simvastatin) Includes ... TheStreet.com (press release) New FDA Approved Labeling For VYTORIN(R) (Ezetimibe/Simvastatin) Includes |